The Montreal General Hospital
Welcome,         Profile    Billing    Logout  
 6 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Garg, Amit
DIALEX, NCT06660277: DIALysis with EXpanded Solute Removal

Not yet recruiting
N/A
4800
Canada
Super High-Flux Dialyzer, expanded hemodialysis, Nipro ELISIO HX, High-Flux Dialyzer, conventional hemodialysis
Western University, Canada, Schulich School of Medicine and Dentistry, ICES, Population Health Research Institute, Nipro Canada Corporation, London Health Sciences Centre
Chronic Kidney Disease Requiring Hemodialysis, End-Stage Kidney Disease (ESKD)
01/30
01/30
NCT04079582: Outcomes of a Higher vs. Lower Hemodialysate Magnesium Concentration (Dial-Mag Canada)

Active, not recruiting
N/A
25000
Canada
Dialysate magnesium formulation of 1.5 mEq/L (0.75 mmol/L)., Dialysate magnesium formulation of ≤1.0 mEq/L (≤0.5 mmol/L).
Lawson Health Research Institute, ICES, Canadian Institutes of Health Research (CIHR)
Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
03/26
03/26
Afif, Waqqas
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
RESOLVE, NCT05608681: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE).

Recruiting
1/2
57
Europe, Canada, RoW
EP-104IAR
Eupraxia Pharmaceuticals Inc.
Eosinophilic Esophagitis
12/25
12/25
NCT03261102: TDM Guided Early Optimization of ADAL in Crohn's Disease

Recruiting
N/A
200
Canada
Adalimumab, Humira
waqqas.afif, AbbVie
Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases
12/23
06/24

Download Options